Search
Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL).
Join us as WA’s cancer research community comes together at the inaugural West Coast Cancer Meeting.
Dysphagia, one of the most common complications in head and neck cancer (HNC) treated with radiotherapy, can severely affect patients’ quality of life. Currently, because no “gold standard” treatment exists, swallowing exercise remains the main rehabilitation strategy for dysphagia. However, patients’ compliance with long-term swallowing exercise is only 40%, thus, greatly compromising outcomes. This article aims to analyze thefactors influencing swallowing exercise compliance in patients with HNC and explains strategies developed to date for improved rehabilitation outcomes.
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors play key roles in cell proliferation, angiogenesis, cell migration, and in some cases, tumor promotion.
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
Associate Professor Lesterhuis said the gel, developed with the help of chemists at The University of Western Australia, could revolutionise the way solid tumours were treated.
A pilot clinical study, led in Australia by a The Kids Research Institute Australia and Perth Children's Hospital researcher, has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.
The Kids Research Institute Australia is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.
Researchers at The Kids Research Institute Australia and UWA will use a $500,000 CUREator grant to progress the development of the first cancer immunotherapy in a tablet.
Four The Kids Research Institute Australia researchers from a diverse range of fields have been named as finalists for the prestigious 2022 Premier’s Science Awards.